Empower Pharmacy responded publicly to a recent lawsuit filed by Eli Lilly, stating that the legal action is an attempt by Big Pharma to restrict access to affordable, personalized healthcare.
“This lawsuit is about more than us,” Empower said in a statement on its website. “It’s about Big Pharma testing its power, challenging healthcare companies like Empower who prioritize personalized, affordable care over profit.”
“It’s Big Pharma’s attempt to limit patient and provider choice and restrict access to individualized treatment,” said the statement.
Eli Lilly filed a lawsuit against Empower Pharmacy in April 2025. The suit alleges that Empower is copying and distributing compounded versions of medications that Lilly manufactures.
“The real reason for the lawsuit,” said Empower, is that “compounding medications, customized for individual needs, threaten” the model of mass-produced commercial drugs.
Compounding pharmacies like Empower create customized medications tailored to individual patient needs, often in cases where commercially available drugs are unsuitable due to allergies, dosage requirements, or delivery methods.
Empower Pharmacy is one of the largest compounding pharmacies in the United States, with a 503A facility for patient-specific prescriptions and a 503B outsourcing facility for office-use medications.
In a 2023 policy paper published in Pharmacy, researchers said that compounding pharmacies play a critical role in expanding medication access, particularly for rare diseases and unmet patient needs.
Empower Pharmacy, based in Houston, Texas, serves tens of thousands of patients and providers across the country and has positioned itself as a leader in pharmaceutical compounding with a focus on quality and regulatory compliance.
